58 citations
,
March 2020 in “Scientific Reports” This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.
49 citations
,
November 2016 in “Frontiers in Pharmacology” This study found that over 26% of patients using Tripterygium wilfordii Hook F experienced adverse events, highlighting the need for better strategies to manage these risks.
June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)” This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.
June 2026 in “Frontiers in Oncology” In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.
22 citations
,
December 2018 in “British Journal of Clinical Pharmacology” This study found that most adverse events reported for HPV vaccines in the VAERS system were non-serious and already known, although less common events suggest the need for further examination.
